Webcast link to Corporate Update Conference Call on Thursday, May 29, 2025 at 8:30 a.m. ET

Webcast link to Third Quarter 2024 Financial Results Conference Call – Friday, November 15, 2024 at 8:30 a.m. ET

Webcast link to the H.C. Wainwright 26th Annual Global Investment Conference – Monday, September 9, 2024 at 7:00 a.m. ET.

Webcast link to Second Quarter 2024 Financial Results Conference Call – Thursday, August 15, 2024 at 8:30 a.m. ET

Webcast link to First Quarter 2024 Financial Results Conference Call – Wednesday, May 15, 2023 at 8:30 a.m. ET

Webcast Link to Fourth Quarter and Full Year for period ended December 31, 2023 on Friday, March 8, 2024 at 8:30 a.m. ET

Webcast Link to H.C. Wainwright 25th Annual Global Investment Conference – Tuesday. September 12, 2023

Webcast link to First Quarter 2023 Financial Results Conference Call – Friday, May 12. 2023 at 8:30 a.m. ET

Webcast link to Fourth Quarter and Full Year 2022 Financial Results Conference Call – Friday, March 31. 2023 at 8:30 a.m. ET

Webcast Link to Third Quarter 2022 Earnings Financial Results Conference Call – Tuesday November 15, 2022 at 8:30 a.m. ET

Webcast link to H.C. Wainwright 24th Annual Global Investment Conference – Monday, September 12, 2022 at 7:00 am ET

H.C. Wainwright & Co. – August 17, 2022 – Article

Webcast Link to Second Quarter 2022 Earnings Financial Results Conference Call – Tuesday, August 16, 2022 at 8:30 a.m. ET

Corporate Presentation May 2022

Webcast Link to First Quarter 2022 Earnings Financial Results Conference Call – Tuesday, May 17, 2022 at 8:30 a.m. ET

BP1003 AACR 2022 Abstract

Webcast Link to 2021 Full Year Earnings Financial Results Conference Call – Friday, March 11, 2022 at 8:30 a.m. ET

Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2.

The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery

Annual Shareholders Presentation Slides – December 2020

STONEGATE Capital Partners December 4, 2019 Report

H.C. Wainwright / BPTH: Safety Testing of Phase 2 AML Trial Completed; Financing Closed; Reiterate Buy; Adjusting PT to $25

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) – January 2019

Stonegate Capital Partners Research Report – August 2018

BP1001 phase I-Ib protocol

Drug Development and Delivery Published Article: DNA THERAPEUTICS – DNAbilize-ING Antisense

Published Article: Evolution of Antisense Oligonucleotides in Oncology

Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01

OncLive interview with Dr. Cortes on BP-100.01 in Patients with Relapsed/Refractory AML

Bio-Path Hopes to Blaze Profitable Path With Antisense Drugs – January 2016